News MSD has gauged its financial hit from Trump tariffs MSD expects to see an additional $200m layered onto its costs this year as a result of President Trump's tariffs, ahead of any pharma-specific levy.
News Roche joins the pharma firms planning big US investments Roche will spend $50bn on manufacturing and R&D facilities in the US, with a pledge to export more medicines from the US than it imports.
News US starts the clock ticking on pharma tariffs The US has launched a national security probe into the national security implications of importing pharmaceuticals, seen as a precursor to tariffs.
News Novartis plans $23bn manufacturing, R&D spend in US Novartis has announced a massive investment in manufacturing and R&D facilities in the US so it can make "100% of its key medicines" there.
News Pharma in a spin as it tries to gauge Trump tariffs impact Pharmaceuticals are exempt from the tariffs revealed by President Donald Trump, for now, but the industry is bracing for what may come next.
News Pharma tariffs "will hurt US consumers most of all" If pharmaceuticals are included in President Trump's 'Liberation Day' tariffs, it is US consumers who will suffer the most, says a new report.